Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Croat Med J ; 61(6): 518-524, 2020 Dec 31.
Article in English | MEDLINE | ID: mdl-33410298

ABSTRACT

AIM: To determine the prevalence of common somatic comorbidities among coronavirus disease 2019 (COVID-19) positive patients in Croatia in the first pandemic wave, and assess the differences in clinical outcomes depending on the presence of comorbidities. METHODS: We analyzed data from patients confirmed to be SARS-CoV-2-positive from February through May 2020. The data were obtained from clinical laboratories, primary health care providers, and hospitals. Previously recorded comorbidities, including diabetes, cancer, circulatory diseases, chronic pulmonary, and kidney disease, were analyzed. RESULTS: Among 2249 patients, 46.0% were men (median age 51 years; median disease duration 27 days). Hospitalization was required for 41.8% patients, mechanical ventilation for 2.5%, while 4.7% of all patients died. Patients who died were significantly older (median 82 vs 50 years, P<0.001) with a higher prevalence of all investigated comorbidities (all p's <0.001), more frequently required mechanical ventilation (34% vs 1%, P<0.001), and had shorter length of hospital stay (median 13 vs 27 days, P<0.001) with no sex preponderance. Patients requiring mechanical ventilation were significantly older (median age 70 vs 51 years, P<0.001), more frequently men (59.6% vs 45.7%, P=0.037), showed a higher prevalence of all comorbidities except ischemic heart and chronic kidney disease (all p's <0.001), and demonstrated a higher case-fatality rate (63.2% vs 3.2%, P<0.001). CONCLUSION: COVID-19 patients who died in the first pandemic wave in Croatia were more likely to suffer previous somatic comorbidities. This corroborates the findings of similar studies and calls for further research into the underlying disease mechanisms, hence providing ground for more efficient preventive measures.


Subject(s)
COVID-19/complications , COVID-19/epidemiology , Comorbidity , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/complications , Croatia/epidemiology , Databases, Factual , Diabetes Complications , Female , Hospitalization , Humans , Kidney Diseases/complications , Lung Diseases/complications , Male , Middle Aged , Neoplasms/complications , Pandemics , Prevalence , Public Health , Respiration, Artificial , Risk Factors
2.
Croat Med J ; 60(6): 488-493, 2019 Dec 31.
Article in English | MEDLINE | ID: mdl-31894913

ABSTRACT

AIM: To determine the prevalence of muscular dystrophy (MD) and spinal muscular atrophy (SMA) in Croatia by use of multiple epidemiological tools. METHODS: This epidemiological study collected data from three national patient registries and one database of a non-governmental organization (NGO) of MD and SMA patients. The study involved all individuals who either had undergone hospital treatment for MD or SMA, had consulted their primary health care providers for MD- and SMA-related symptoms, were listed as disabled due to MD or SMA, or were members of the mentioned NGO in 2016. In order to prevent double entries, we created a new database of all living individuals, each with a unique identification number. The prevalence rates for 2016 were calculated by age and sex groups. RESULTS: There were 926 patients diagnosed with MD (544 men). Most men diagnosed with MD were in the age group 10-19, whereas most women were in the age group 50-59. MD prevalence in Croatia was 22.2 per 100000 population. There were 392 patients diagnosed with SMA (198 men). Most men with SMA were in the age group 50-59, whereas most women were in the age group 60-69. SMA prevalence in Croatia was 9.3 per 100000 population. CONCLUSION: SMA prevalence rate in Croatia is similar to SMA prevalence worldwide. However, MD prevalence rate is higher than worldwide estimates. This difference could be attributed to the fact that we could not confirm whether every patient registered in these databases actually met the diagnostic criteria for MD and SMA.


Subject(s)
Muscular Atrophy, Spinal/epidemiology , Muscular Dystrophies/epidemiology , Adolescent , Adult , Age Distribution , Aged , Child , Child, Preschool , Croatia/epidemiology , Female , Government Agencies , Humans , Infant , Infant, Newborn , Male , Middle Aged , Organizations , Prevalence , Referral and Consultation , Registries , Sex Distribution , Young Adult
3.
Croat Med J ; 59(2): 65-70, 2018 Apr 30.
Article in English | MEDLINE | ID: mdl-29740990

ABSTRACT

AIM: To update the estimate of multiple sclerosis (MS) prevalence in Croatia using multiple epidemiological tools. METHODS: This level IV, epidemiological study gathered data from three national patient registries and one database of a non-governmental MS patients' organization. Data were extracted on all individuals who had undergone hospital MS treatment, consulted their primary health care providers about MS-related symptoms, been listed as having MS-related disability, or been members of the mentioned non-governmental organization in 2015. A new database was formed, in which all living individuals were identified using a common identification number to prevent double entries. The prevalence rates in 2015 were calculated by age and sex groups. RESULTS: In total, 6160 patients diagnosed with MS were identified (72% women). Most women with MS were 50-59 years old and most men were 40-49 years old. The overall MS prevalence rate was 143.8 per 100 000 population. CONCLUSION: The calculated MS prevalence rate in Croatia in 2015 was more than twice as high as the estimate from 2013. This difference warrants further research into MS epidemiology in Croatia and calls for a rational allocation of funds and human resources to provide adequate care and support to MS patients.


Subject(s)
Multiple Sclerosis/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Croatia/epidemiology , Databases, Factual , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Middle Aged , Prevalence , Registries , Young Adult
5.
Acta Med Croatica ; 65(3): 227-35, 2011.
Article in Croatian | MEDLINE | ID: mdl-22359890

ABSTRACT

INTRODUCTION: Articular cartilage is an avascular and aneural tissue lacking lymph drainage, hence its inability of spontaneous repair following injury. Thus, it offers an interesting model for scientific research. A number of methods have been suggested to enhance cartilage repair, but none has yet produced significant success. The possible application of the aforementioned methods has brought about the necessity to evaluate their results. The objective of this study was to analyze results of a study of the effects of the use of TGF-beta gene transduced bone marrow clot on articular cartilage defects using ICRS visual histological assessment scale. METHODS: The research was conducted on 28 skeletally mature sheep that were randomly assigned to four groups and surgically inflicted femoral chondral defects. The articular surfaces were then treated with TGF-beta1 gene transduced bone marrow clot (TGF group), GFP transduced bone marrow clot (GFP group), untransduced bone marrow clot (BM group) or left untreated (NC group). The analysis was performed by visual examination of cartilage samples and results were obtained using ICRS visual histological assessment scale. The results were subsequently subjected to statistical assessment using Kruskal-Wallis and Mann-Whitney tests. RESULTS: Kruskal-Wallis test yielded statistically significant difference with respect to cell distribution. Mann-Whitney test showed statistically significant difference between TGF and NC groups (P = 0.002), as well as between BM and NC groups (P = 0.002 with Bonferroni correction). DISCUSSION: Twenty-six of the twenty-eight samples were subjected to histologic and subsequent statistical analysis; two were discarded due to faulty histology technique. Our results indicated a level of certainty as to the positive effect of TGF-beta1 gene transduced bone marrow clot in restoration of articular cartilage defects. However, additional research is necessary in the field. One of the significant drawbacks on histologic assessment of cartilage samples were the errors in histologic preparation, for which some samples had to be discarded and significantly impaired the analytical quality of the others. Defects of structures surrounding the articular cartilage, e.g., subchondral bone or connective tissue, might also impair the quality of histologic analysis. Additional analyses, i.e. polarizing microscopy should be performed to determine the degree of integration of the newly formed tissue with the surrounding cartilage. The semiquantitative ICRS scale, although of great practical value, has limitations as to the objectivity of the assessment, taking into account the analytical ability of the evaluator, as well as the accuracy of semiquantitative analysis in comparison to the methods of quantitative analysis. CONCLUSION: Overall results of histologic analysis indicated that the application of TGF-beta1 gene transduced bone marrow clot could have measurable clinical effects on articular cartilage repair. The ICRS visual histological assessment scale is a valuable analytical method for cartilage repair evaluation. In this respect, further analyses of the method value would be of great importance.


Subject(s)
Bone Marrow Transplantation , Cartilage, Articular/pathology , Transforming Growth Factor beta1/pharmacology , Wound Healing , Animals , Cartilage, Articular/physiopathology , Gene Transfer Techniques , Green Fluorescent Proteins , Sheep , Transduction, Genetic , Transplantation, Autologous , Wound Healing/drug effects
6.
Article in English | MEDLINE | ID: mdl-36994328

ABSTRACT

Aim: The study aims to investigate the effects of the COVID-19 pandemic on diabetes management and diabetes patients' healthcare utilization patterns in Croatia. Methods: Using data contained in the Croatian diabetes registry (CroDiab), Central Health Information System of the Republic of Croatia (CEZIH), and the Croatian hospitalization database (BSO), indicators including the total number of registered diabetes patients, number of newly diagnosed diabetes cases, number of diabetes-related primary care visits and hospitalizations, and key diabetes control indicators were analyzed. Yearly values from 2017 until 2020 were compared. Results: The age-adjusted prevalence rate increased significantly from 2017 until 2019 (2017: 6,858/100,000; 2018: 7,053/100,000; 2019: 7,160/100,000). In 2020 the age-adjusted prevalence rate was 7,088/100,000, but the decrease was insignificant compared to 2019. The age-adjusted rate of new cases decreased from 2017 until 2019 (2017: 910/100,000; 2018: 876/100,000; 2019: 845/100,000), with a significant decrease in 2020 (692/100,000) compared to 2019. The number of diabetes panels increased from 2017 (117,676) to 2018 (131,815), with a slight decrease in 2019 (127,742) and a sharp decrease in 2020 (104,159). A similar trend was observed regarding the numbers of diabetes patients with panels, visits to primary healthcare providers for diabetes-related problems and diabetes patients who visited their primary healthcare provider. A slightly different trend was observed regarding diabetes-related hospitalizations. In 2017 there were 91,192 diabetes-related hospitalizations; the number decreased to 83,219 in 2018, increased again to 102,087 in 2019 and decreased to 85,006 in 2020. The number of hospitalized diabetes patients displayed a similar tendency. Conclusion: The COVID-19 pandemic has had a negative effect on the utilisation of healthcare by diabetes patients, which may have long-term consequences for their general health.

7.
Adv Ther ; 35(3): 261-288, 2018 03.
Article in English | MEDLINE | ID: mdl-29508154

ABSTRACT

INTRODUCTION: The objective was to evaluate efficacy/safety of complementary and alternative medicine (CAM) methods for generalized anxiety disorder (GAD) based on randomized controlled trials in adults. METHODS: Data sources. Six electronic databases ("generalized anxiety (disorder)" and "randomized trial") and reference lists of identified publications were searched to March 2017. STUDY SELECTION: Eligibility: full-text publications (English, German language); CAM versus conventional treatment, placebo/sham or no treatment; GAD diagnosed according to standard criteria; and a validated scale for disease severity. Of the 6693 screened records, 32 were included (18 on biologically-based therapies, exclusively herbal preparations; eight on manipulative and body-based therapies; and three on alternative medical systems and three on mind-body therapies). DATA EXTRACTION: Cochrane Collaboration methodology was used for quality assessment and data extraction. RESULTS: Direct comparisons of Kava Kava (Piper methysticum) extracts to placebo (4 quality trials, n = 233) were highly heterogeneous. Network meta-regression reduced heterogeneity and suggested a modest Kava effect [end-of-treatment Hamilton Anxiety scale score difference adjusted for baseline scores and trial duration: - 3.24 (95% CI - 6.65, 0.17; P = 0.059), Kava Kava 4 arms, n = 139; placebo 5 arms, n = 359]. Lavender (Lavandula angustifolia) extract (1 quality trial, 10 weeks, n = 523) and a combination of extracts of C. oxycantha, E. californica and magnesium (1 quality trial, 12 weeks, n = 264) were superior to placebo and balneotherapy was superior to paroxetine (1 quality trial, 8 weeks, n = 237) indicating efficacy. All other trials were small and/or of modest/low quality and/or lacked assay sensitivity. Safety reporting was poor. CONCLUSION: Evidence about efficacy/safety of most CAM methods in GAD is limited. Apparent efficacy of certain herbal preparations and body-based therapies requires further confirmation.


Subject(s)
Anxiety Disorders/therapy , Complementary Therapies/methods , Humans , Randomized Controlled Trials as Topic
SELECTION OF CITATIONS
SEARCH DETAIL